US Stocks
Immunic Inc
Immunic Inc

Immunic Inc (IMUX)


  • $







Key Stats

Today Low/High$10.97 / $11.43
52 Week Low/High$6.96 / $28.21
Market Cap$312.63M

Company Details

Immunic, Inc. is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including relapsing-remitting multiple sclerosis, ulcerative colitis, Crohn's disease, and psoriasis. Immunic is developing three small molecule products: its lead development program, IMU-838, is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect; IMU-935 is an inverse agonist of RORγt; and IMU-856 targets the restoration of the intestinal barrier function. Immunic announced positive results from its phase 2 EMPhASIS trial of IMU-838 in patients with relapsing-remitting multiple sclerosis, reporting achievement of both primary and key secondary endpoints with high statistical significance. IMU-838 is also in phase 2 clinical development for ulcerative colitis and COVID-19, with an additional phase 2 trial considered in Crohn's disease. An investigator-sponsored proof-of-concept clinical trial for IMU-838 in primary sclerosing cholangitis is ongoing at the Mayo Clinic.
OrganisationImmunic Inc
HeadquatersPlanegg, Bayern, Germany
IndustryPharmaceuticals: Major
CEODaniel Vitt

Discover more

Frequently Asked Questions

What is Immunic Inc (IMUX) share price today?

Can Indians buy Immunic Inc (IMUX) shares?

How can I buy Immunic Inc (IMUX) shares from India?

Can Fractional shares of Immunic Inc (IMUX) be purchased?

What are the documents required to start investing in Immunic Inc (IMUX) stocks?